GHK-Cu: Four Decades of Copper Peptide Science and What Researchers Are Finding

Glycyl-L-histidyl-L-lysine copper (GHK-Cu) is one of the most studied copper-binding peptides in dermatological and wound-healing research. First isolated from human plasma in the early 1970s by Dr. Loren Pickart, this tripeptide forms a high-affinity complex with copper(II) ions and has since accumulated over four decades of research literature across wound healing, collagen synthesis, gene expression modulation, and skin regeneration.[1]

What makes GHK-Cu particularly interesting from a research standpoint is not just its direct biological effects — but its apparent influence on gene expression at scale. Connectivity mapping studies from the Broad Institute found GHK modulated over 4,000 human genes, including 31.2% of the entire human genome's gene activity when measured above a 50% change threshold.[2]

GHK (Gly-His-Lys) is a naturally occurring tripeptide found in human plasma, saliva, and urine. Plasma concentrations are highest in youth — approximately 200 ng/mL at age 20 — declining significantly to around 80 ng/mL by age 60.[3] This age-related decline correlates with decreasing tissue repair capacity and wound healing efficacy observed as organisms age.

The peptide binds copper(II) ions with high affinity, forming the GHK-Cu complex that shows substantially greater biological activity than GHK alone. The copper component serves as an essential cofactor for key enzymes involved in collagen cross-linking and stability — particularly lysyl oxidase and lysyl hydroxylase. Without adequate copper availability, newly synthesized collagen fibers remain structurally weak and prone to degradation.[4]

GHK-Cu's most well-documented effect in laboratory models is its influence on collagen biology. Research by Maquart et al. (1988) demonstrated that GHK-Cu at extremely low, non-toxic concentrations (1–10 nanomolar) stimulated both the synthesis and breakdown of collagen and glycosaminoglycans — along with modulation of metalloproteinase (MMP) activity and their tissue inhibitors (TIMP-1).[5]

This dual stimulation/breakdown effect is not paradoxical — it reflects healthy extracellular matrix (ECM) turnover, the process by which damaged collagen is degraded and replaced with new, structurally sound collagen fibrils.

In in-vitro models, GHK-Cu has been shown to:

• Stimulate Type I and Type III collagen synthesis by fibroblasts
• Upregulate decorin, a proteoglycan that organizes collagen fiber architecture
• Enhance chondroitin sulfate and dermatan sulfate production
• Promote fibroblast proliferation and keratinocyte migration
• Support angiogenesis in wound beds through multiple complementary pathways[1][6]

One of the most compelling areas of GHK-Cu research involves its influence on gene expression profiles. Analysis using the Broad Institute's Connectivity Map revealed GHK significantly altered the expression of 4,000+ genes — with 47 DNA repair genes stimulated and 5 suppressed at a ≥50% change threshold.[2]

Downstream effects identified in studies include:

• Activation of genes associated with tissue remodeling and ECM maintenance
• Suppression of genes linked to chronic inflammation and tissue catabolism
• Apparent "reset" of gene expression profiles in aged skin cells toward patterns more characteristic of younger cells[7]

A 2025 IRB-approved human clinical trial (Yuvan Research, California) involving 21 women applied a stable GHK-Cu topical gel daily for 3 months and measured skin collagen density via biopsy. Results showed an average 28% increase in collagen density across participants, with the top quartile achieving 51% increases.[8]

Animal and in-vitro models of wound healing consistently demonstrate GHK-Cu's multi-faceted role in tissue repair:

• Accelerated wound closure rates in skin punch wound models in normal, diabetic, and aged mice
• Increased blood vessel formation (angiogenesis) at wound sites in rabbit models
• Elevated antioxidant enzyme levels in wound tissue
• Reduction in TNF-alpha (a key pro-inflammatory cytokine) and stimulation of collagen synthesis in diabetic wound models
• Systemic wound-healing effects in rat, mouse, and pig models following local application[1][6]

Wound healing activity of GHK-Cu has also been confirmed in several clinical contexts. Studies of diabetic ulcers and Mohs surgical wounds found that GHK-Cu preparations significantly improved re-epithelialization rates and overall wound healing outcomes.[9]

A series of controlled clinical studies in photoaged skin have examined topical GHK-Cu formulations:

• Abdulghani et al. (1999): In a head-to-head comparison against vitamin C and retinoic acid, GHK-Cu resulted in measurable collagen increases in 70% of volunteers — outperforming both established comparators.[10]
• Leyden et al. (two trials): 71 women with mild-to-advanced photoaging applied GHK-Cu facial cream daily for 3 months. Results showed increased skin density and thickness, reduced sagging, and reduction in fine lines and wrinkles.[11]
• Copper Tripeptide Pilot Study: A copper tripeptide topical pilot study demonstrated increased skin thickness and elasticity, improved hydration, and boosted collagen synthesis in aged skin biopsies.[11]

GHK-Cu is widely used as a research compound for:

• In-vitro fibroblast proliferation and collagen synthesis assays
• Wound closure model studies
• Gene expression modulation experiments
• Metalloproteinase activity research
• Angiogenesis pathway studies

At Bluenova Bio, GHK-Cu is supplied as lyophilized powder, independently tested for purity in US-based third-party labs. All sales are for research purposes only.